Intestinal FXR agonism, by treatment with a gut-restricted FXR agonist fexaramine, reduced the diet-induced obesity and insulin resistance, and promoted the browning of WAT, accompanying a drastic increase in the enteric FGF15 levels [118]. The gene discussed is NR1H4; the disease is obesity disorder.